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Abstract
In the general population, mild renal impairment is associated with increases risk for coronary
artery disease and stroke, suggesting that cardiovascular disease begins to develop early in the
natural history of renal dysfunction. Patients with renal failure are known to be at increased risk of
death following acute myocardial infarction or congestive heart failure.
In such sense, anticoagulation in addition to antiplatelet inhibitor drugs became the standard of
care, particularly, among high risk unstable angina patients associated with a scarce side effects.
The Nadroparin calcium Versus Enoxaparin (NaVe) Study will evaluate in a head to head basis the
anti Xa activity reached by nadroparine or enoxaparine, both low molecular weight heparins, in
patients at high risk for ischemic episodes, and renal insufficiency to eventually be undergone to
angiographic diagnosis studies, and in consequence proposing the best anticoagulant strategies for
these patients before being invasively treated.
Patients will be randomly assigned to one of the two groups: Group 1: thirty patients will be given
with subcutaneous enoxaparine injections into the abdominal wall in a dose of 0,85 mg/kg every 12
hours for a maximum of 48 hours. A saline infusion dose will be given in between. Total number
of injections: 6. Group 2:Thirty patients will be receiving subcutaneous injections into the
abdominal wall in a doses of 30% less in relationship with his / her body weight every 8 hours for
a maximum of 48 hours.
In order to achieve the goal of the study, the antiXa activity will be measure using venous blood
samples taken as follows: Group 1:*Within 3rd and 4 hour of the second doses of HBPM for
enoxaparine.*Within 11 th and 12 th hour next to fourth doses of enoxaparine. Group 2: *Within
3rd and 4 th hour next to 3rd doses of HBPM for the nadroparine.*Within 7th and 8th hour next to
4th doses HBPM for the nadroparine.
The primary end point is to analyze during the in-hospital stay phase the stability of the anti Xa
activity within the therapeutic ranges which will be estimated between 0.5 to 1.0 IU during the first
48 hours.
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In the general population, mild renal impairment is asso-
ciated with increases risk for coronary artery disease and
stroke, suggesting that cardiovascular disease begins to
develop early in the natural history of renal dysfunc-
tion[1]. Patients with renal failure are known to be at
increased risk of death following acute myocardial infarc-
tion or congestive heart failure[2].
Furthermore, their risk of Cardiovascular disease was
higher if the serum creatinine concentration was > 1.5 mg/
dl, a result which is supported by findings in a recent
study[3].
The prevalence of mild renal dysfunction, defined as CC
<60 ml/min, in heart failure trials was 25,9 % in SOLV
Prevention Trial, 55.5% in Left Ventricular Systolic Dys-
function (SOLVD) treatment trial [4] and they found a
parallel relation between total mortality, all cause death
and arrhythmic death with renal dysfunction.
The benefits of administering low molecular weight
heparins as a short-term treatment during the acute
phases of coronary disease are widely acknowledged,
worldwide accepted and embodied to most of protocols
[5-7].
The low molecular weight heparins produce a more pre-
dictable anticoagulant response than unfractionated
heparin, reflecting a better bioavailability, longer half-life,
and dose independent clearance than the regular heparin.
The plasma half-life of low molecular weight heparins is
two to four times as long as that of unfractionated
heparin, ranging from two to four hours after intravenous
injection and from three to six hours after subcutaneous
injection the inhibitory activity of low molecular weight
heparins against thrombin, reflecting the more rapid
clearance of longer heparin chains, essentially among
apparently healthy volunteers and patients without renal
dysfunction.
In addition to this, the low molecular weight heparins
(LMWH) reduced the combined incidence of myocardial
infarction and death compared with another therapies
such as unfractionated heparin associated with less sensi-
tive administration, particularly enoxaparin [8].
In such sense, anticoagulation in addition to antiplatelet
inhibitor drugs became the standard of care, particularly,
among high risk unstable angina patients associated with
a scarce side effects.
Both, fractionated and un fractionated heparins have a
partial elimination through renal function. In the case of
enoxaparine, the drug has shown a longer half-life in
blood among patients with renal impairment than those
treated with conventional heparin. According to this, Col-
let et al [9]have found, in a sole previous and prospective
paper that a therapeutic range between 0.5 and 1 IU/ml of
activated anti factor X a could be reached with a doses of
0.85 mg/kg in patients with renal insufficiency whose cre-
atinine clearence is estimated between >30 and < 60 ml/
min.
In such sense, a non enough body of evidences is support-
ing how to attempted to proceed with the treatment of
these patients that daily are given complete anticoagulants
having in consideration the renal function in order to
avoid the accumulation of the doses with unpredictable
hemorrhagic consequences.
Even more, various LMWHs were investigated and there
were some inconsistencies of efficacy findings between
those trials in which they were tested [10].
Methods/Design
Study objetive
The The Nadroparin calcium Versus Enoxaparin (NaVe)
Study will evaluate in a head to head basis the anti Xa
activity reached by nadroparine or enoxaparine, both low
molecular weight heparins, in patients at high risk for
ischemic episodes, and renal insufficiency to eventually
be undergone to angiographic diagnosis studies, and in
consequence proposing the best anticoagulant strategies
for these patients before being invasively treated.
The hypothesis is to evaluate the use low reduced doses
more frequently and / or the time interval between one
intake, and the other giving place to an homogeneous
movement of the anti-Xa activity within a therapeutic
range.
Protocol
This study will be conducted following the Helsinki dec-
laration the good clinical practices established by the
International conference of harmonization, and any other
national or international in force legislation. Patients
must sign an Informed consent form. The Independent
Ethic Committee of our Institute, approved the protocol.
This study is prospective, controlled, randomly assigned,
in a double blind fashion (patient-hematologic team).
Patients suffering from an acute coronary syndrome as
type IIIb of Braunwald's Classification will be eligible for
the trial.Page 2 of 6
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1) unstable angina clase IIIb Braundwald's classification:
chest pain that occurs in repose between 48 hours previ-
ously no lasting more than 20 minutes to admission plus
new ST-T changes in at least two contiguous leads (ST ele-
vation or depression ≥ 0.1 mV and/or T wave inversion).
2) Infarction without ST segment elevation.
3) Women's must be 6-month post menopause or tuba
uterine ligature.
Exclusion
1) Patients with more than 100 kilograms.
2) Patients that had been treated with anticoagulants dur-
ing the last 7 days prior to be admitted or currently under
coagulation.
3) Women that could get pregnant, pregnant or nursing
period because the side effects or these drugs are still
unknown.
4) Patients with background of major haemorrhage, active
bleeding within the last 2 weeks or wit blood discrasia.
5) patients with less than 75 × 103 platelets per mm3.
6) patients with thrombocytopenia induced by heparin.
7) Patients with active peptic ulcer.
8) Patients with neurological surgery or neurological
impairment such as antecedents of intracraneal hemor-
rhage, subdural hematoma, epidural hematoma, any
prior Stroke from any origin.
9) Patients with systolic hypertension at enrolment major
of 180/100 MmHg.
10) Patients with renal insufficiency undergoing dialysis.
11) Patients minor than 21 years of age.
12) Those patients that do not want to sign the consent
informed.
At admission, an electrocardiogram and blood sample
will be obtained to measure platelet, creatinine, hemo-
globin, enzymatic dosages, creatinine clearance.
From those, a total of 60 patients will be enrolled if renal
function disorder is determined by creatinine clearance
(no less than 30 ml/min determined by creatinine
clearence (no minor than 30 ml/minutes or major than
60 ml minutes) using the Cockroft-Gault formula [11]
Once that informed consent was obtained, the anti
thrombotic therapeutic is initiated.
All the patients will be randomly allocated to the follow-
ing strategies: nadroparine or enoxaparine, plus anti
ischemic medical therapy according with the interna-
tional recommendations [12,13].
Patients will be randomly assigned to one of the two
groups:
Group 1: thirty patients will be given with subcutaneous
enoxaparine injections into the abdominal wall in a dose
of 0,85 mg/kg every 12 hours for a maximum of 48 hours.
A saline infusion dose will be given in between. Total
number of injections: 6
Group 2:Thirty patients will be receiving subcutaneous
injections into the abdominal wall in a doses of 30% less
in relationship with his / her body weight every 8 hours
for a maximum of 48 hours. Total number of injections: 6
Angiographic study: accomplished 48 hours of adminis-
tration of low molecular weight heparins (routine thera-
peutic phase).
Those patients submitted to an angiographic study, will
be previously treated with N acetylcistein as standard pro-
cedure in order to protect renal function before medium
contrast side effects. Catheterizations with be performed
12 hours after the last doses of the LMWHs was given.
Since the range of antiXa will be measured within the
research team the haematologist and biochemist will be
not given the patient information in order to protect the
double blind strategy. The team at the Coronary Care Unit
(CCU) will remain unblended for the prescriptions of
drugs. The haematological team will remain blinded for
the prescription of the drugs at the CCU.
Data registration
Every patient will have complete personal records and
individual registration form with all data both clinical and
diagnostic needed in this study.
Laboratory
In order to achieve the goal of the study, the antiXa activ-
ity will be measure using venous blood samples taken as
follows:Page 3 of 6
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*Within 3rd and 4hour of the second doses of HBPM for
enoxaparine.
*Within 11th and 12th hour next to fourth doses of enox-
aparine. Table 1.
Group 2
*Within 3rd and 4th hour next to 3rd doses of HBPM for
the nadroparine.
*Within 7th and 8th hour next to 4th doses HBPM for the
nadroparine. Table 1.
Once the venous blood samples are obtained will be
placed into tubes with sodium citrate using for its analysis
a chromogenic essay.
To guarantee the double mind procedure the ampoule
will be stored, provided and given by the coronary unit
team in the character of no double blind team.
The lower level of sensing detection will be determinate.
Pharmacokinetics analysis in each patient will be
obtained by individual characteristics taking into consid-
eration that the maximum concentration should be
detected near the second shot of heparin that verify the
sample to be obtained within 3 to 4 hours after the shot.
Since all the samples will be obtained in the same period
of time the inter individual variability will be equal to
zero.
In addition, given that the traditional formula of the cre-
atinine clearence could not correctly shows the glomerula
filtration, in the final analyses will be included the age
and the body mass.
Primary end point
The primary end point is to analyze during the in-hospital
stay phase the stability of the anti Xa activity within the
therapeutic ranges which will be estimated between 0.5 to
1.0 IU during the first 48 hours.
Secondary end points
Major bleeding complications
They are defined as: 1) intracraneal hemorrhage, with or
without neurological secuelae. 2) The need of any transfu-
sion due to the descending of hemoglobin more than > 3
mg.
Bleeding complications treatment
First, discontinuation of the low molecular weight
heparin under study.
Secondly, protamine and hemoderivates will be indicated
in the presence of descending hemoglobin, major bleed-
ing and in cases of life threatening risk according with the
international rules [12].
Study Termination
The study will terminated in those cases in which the
patient wishes to withdraw the inform consent or in the
case that the research team detects any bleeding complica-
tion that makes to presume an excess of the activity of
anti-Xa over 1 IU/ml.
Discussion
Pharmacokinetic study is essential for dose recommenda-
tions but data in high-risk patients are often scant because
of technical and ethical problems. The population
approach provides the opportunity to deal with sparse
data obtained in patients treated during usual care. In our
study, we will include patients with renal failure as com-
pared to major trials. In order to identify the pathophysi-
ologic factors that cause changes in the dose-
concentration relationship, non-restrictive inclusion crite-
ria will be applied.
In patients treated with enoxaparin for unstable angina, a
slightly higher plasma half-life about 5 hours was how-
ever is also found. A similar increase has been reported in
patients with other extremes conditions (obese patients or
Table 1: Drug administration and sample collections.
Group 1 Enoxaparin Group 2 Nadroparine Calcium
Subcutaneous injection at:
Day 1 Hour 8 – 16 – 20 Hour 8 – 16 – 20
Day 3 Hour 8 – 16 – 20 Hour 8 – 16 – 20
Blood samples taken at:
Day 1 Hour 11 PM Hour 11 PM
Day 3 Hour 6 AM Hour 11 PMPage 4 of 6
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to a reduction of the elimination rate (i.e., clearance) of
enoxaparin. As enoxaparin shows a predominant renal
elimination, this result could be linked to age-related
decline in renal function. However, in the final model, age
(but not creatinine clearance nor serum creatinine level)
could be the only covariate related to low molecular
weight heparin clearance. Due to the Cockroft and Gault
mathematical formula for old patients and the inclusion
of younger patients with renal failure, mean creatinine
clearance could be lower in our study. Furthermore, it has
been suggested by several previous studies that the Cock-
roft and Gault formula is not reliable for the correct
assessment of the glomerular filtration rate, particularly in
the elderly. Thus, the reduction of apparent clearance with
age may be related to a reduction of renal filtration which
is not accurately estimated by the surrogate marker creati-
nine clearance but only by the age of patients.
In prior studies, fixed (1 mg/kg twice a day) weight-
adjusted dosing of enoxaparin is appropriate for most
patients, our findings establish that a dosage reduction of
25% to 33% of the usual recommended dose would be
needed in elderly patients and patients with renal failure
in order to achieve the recommended therapeutic range of
0.5 to 1.0 IU/mL for anti-Xa activity. Even if the optimal
level of anti-Xa neutralization has not been clearly stated,
most trials have shown benefit of enoxaparin within this
range and evidence suggests an increased risk of bleeding
for maximal levels above 1 IU/ml[13].
In addition, clinical observations also suggest a need for
dosage reduction in particular population. Collet et al 9
have thus found that the therapeutic range of 0, 5–1 IU/
ml for anti-Xa activity will be reached with only 0, 64 mg/
kg of enoxaparine in patients with severe renal failure
(creatinine clearance < 30 ml/min) and 0, 85 mg/kg for
those with a creatinine clearance between 30 and 60 ml/
min.
Questions to be answered
Mildly elevated serum creatinine concentration has been
proposed to be a marker of increased risk for mortality
due to cardiovascular disease[14]. It has also been shown
to be associated with the extent of coronary atherosclero-
sis independently of conventional risk factors; in this case,
it is thought to indicate generalized vascular disease
denoting early nephrovasculopathy in correlation with
established atherosclerotic risk factors. In other studies,
high serum creatinine concentration has been associated
with increased mortality in hypertensive patients, elderly
patients, and in those with myocardial infarction or
stroke.
An increase on mayor bleeding was found as renal dys-
function worsened. Patients with renal impairment have
decreased platelet function and elevated procoagulant
activity, as reported by the National Kidney Foundation
Task Force, but it is reasonable and strongly recom-
mended to prescribe aspirin (75 to 325 mg/day) to reduce
the risk for subsequent events in patients with coronary
artery disease[15]. Studies are lacking regarding revascu-
larization management in renal dysfunction patients,
mainly because they have been excluded or were nor stud-
ied as a subgroup in the clinical trials. The criteria on
which renal patients should undergo invasive diagnostic
and therapeutics procedures have not been outlined yet.
Paradoxically, overall utilization of antiplatelet agents like
aspirin or clopidrogrel, beta blockers and statins were less
frequently prescribed in renal disfunction patients, since it
is well documented that the National Kidney Foundation
Task Force strongly recommend them to disminish cardi-
ovascular events at follow up[15].
Since the heparins are metabolized by the kidney, facing
renal dysfunction these type of heparins could not be cor-
rectly eliminated inducing an inadequate accumulation of
them in blood.
Unfortunately, the optimal dose in patients with renal
dysfunction and acute coronary syndrome, has not yet
been established.
Thus, we propose in the present study to test the hypoth-
esis that a minimal useful dose may be achieved in the
frame of renal dysfunction avoiding bleeding complica-
tions and or loosing efficacy in an acute coronary event.
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